What about relevant research that isn’t reported at all?
“...failure to provide adequate, publicly available reports of the results of clinical trials does an injustice to the patients who have participated in them...”
Publication bias can kill!

Cowley et al. 1993: “When we carried out our study in 1980 we thought that the increased death rate that occurred in the drug group was an effect of chance... The development of the drug was abandoned for commercial reasons, and this study was therefore never published; it is now a good example of ‘publication bias’. The results described here...might have provided an early warning of trouble ahead.”
At the peak of their use in the late 1980s, it has been estimated that these drugs killed as many Americans every year as were killed during the whole of the Vietnam war.

Welcome to the WHO International Clinical Trials Registry Platform

The mission of the WHO Registry Platform is to ensure that a complete view of research is accessible to all those involved in health care decision making. This will improve research transparency and will ultimately strengthen the validity and value of the scientific evidence base.

The registration of all interventional trials is a scientific, ethical and moral responsibility.
An illustration of the way that clinical researchers and ‘the system’ are failing patients
What is the best treatment for vitiligo?
Cochrane Review

Whitton ME, Ashcroft DM, Barrett C W, Gonzalez U.

Interventions for vitiligo.

The Cochrane Database of Systematic Reviews 2006, Issue 1.
Findings (1)

- 19 RCTs, generally short-term, poorly designed, and poorly reported
- No two trials compared the same interventions
- No trials on cosmetic camouflage or depigmentation
- Only one study examined the psychological effects of treatments
Findings (2)

• Large variations in methods for scoring re-pigmentation.
• No reliable data on patient-important outcomes or quality of life measures.
• Many trials too short-term to indicate any relevant longer term effects, whether beneficial or unwanted.
Findings (3)

Limited evidence, from single randomised trials, that there may be short-term benefits from:
- corticosteroids
- topical tacrolimus
- various forms of ultraviolet light
- gingko biloba
- skin grafting
Are there any potentially relevant unpublished trials?
Are there any potentially relevant unpublished trials?

Yes, there’s an unpublished controlled trial of pseudocatalase.
Before pseudocatalase
After pseudocatalase
• A 12-month RCT of pseudocatalase was done in 1997.
• The trial has still not been reported publicly in 2008.
• The research participants have not been told anything about the study findings.
• The responsible NHS Research Governance Department has so far been unable to account for this.
In summary

Over a period of more than 40 years, clinical researchers have:

• failed to do randomised trials of good quality

• failed to report all of the trials to which patients have contributed; and

• are only now beginning to show signs of collaborating in clinical research to meet the information needs of patients with vitiligo.
Promoting improvements in the quality of reports of research should help to improve the quality and relevance of research.
Some ways to improve the relevance of research to patients and clinicians
1. Find out which unanswered questions are of importance to patients, carers and clinicians
### Research priorities among patients with osteoarthritis of the knee compared with researchers’ priorities (Tallon et al. 2000).

<table>
<thead>
<tr>
<th>Interventions for osteoarthritis of the knee</th>
<th>Research priorities among 67 patients</th>
<th>Interventions evaluated in 460 RCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Per cent</td>
</tr>
<tr>
<td>Knee replacement</td>
<td>24</td>
<td>35.8</td>
</tr>
<tr>
<td>Education and advice</td>
<td>14</td>
<td>20.9</td>
</tr>
<tr>
<td><strong>Drugs</strong></td>
<td>6</td>
<td><strong>9.0</strong></td>
</tr>
<tr>
<td>Complementary therapy</td>
<td>4</td>
<td>6.0</td>
</tr>
<tr>
<td>Physical therapies</td>
<td>2</td>
<td>3.0</td>
</tr>
<tr>
<td>Miscellaneous others</td>
<td>16</td>
<td>23.9</td>
</tr>
<tr>
<td>No intervention</td>
<td>1</td>
<td>1.5</td>
</tr>
</tbody>
</table>
2. Find out which outcomes are important to patients
OMERACT: An international initiative to improve outcome measurement in rheumatology
Peter Tugwell*1, Maarten Boers2, Peter Brooks3, Lee Simon4, Vibeke Strand5 and Leanne Idzerda6

Abstract
OMERACT is the acronym for an international, informally organized network initiated in 1992 aimed at improving outcome measurement in rheumatology. Chaired by an executive committee, it organizes consensus conferences in a 2-yearly cycle that circles the globe. Data driven recommendations are prepared and updated by expert working groups. Recommendations include core sets of measures for most of the major rheumatologic conditions. Since 2002 patients have been actively engaged in the process.
Priority treatment outcome from a survey of patients with rheumatoid arthritis was not pain.
Priority treatment outcome from a survey of patients with rheumatoid arthritis was not pain. It was fatigue!
1 (a) What are the adverse effects associated with long-term use of short and long-acting bronchodilators; inhaled and oral steroids; and combination and additive therapies in adults?
(N.B. this includes children aged 12 years old and over)

1 (b) What are the adverse effects associated with long-term use of short and long-acting bronchodilators; inhaled and oral steroids; and combination and additive therapies in children?
STROBE and MOOSE

STROBE Statement
STrngthening the Reporting of OBServational studies in Epidemiology

STROBE checklist, version 4 (as published in Oct / Nov 2007)
STROBE checklist for cohort, case-control, and cross-sectional studies (combined)
Checklist for cohort studies
Checklist for case-control studies
Checklist for cross-sectional studies

Meta-analysis of Observational Studies in Epidemiology
A Proposal for Reporting
3. Make uncertainties explicit
“As we know, there are known knowns. There are things we know we know.

“We also know there are known unknowns. That is to say we know there are some things we do not know.

“But there are also unknown unknowns, the ones we don't know we don't know.”

Donald Rumsfeld
Database of Uncertainties about the Effects of Treatments

DUETs: www.duets.nhs.uk

An initiative of the National Therapeutic Ignorance Service
Uncertainties in DUETs

[June 2008]

- Cancer (23)
- Cardiovascular diseases (27)
- Ear nose and throat disorders (118)
  - Eyes and vision (1)
  - Gastroenterological and liver diseases (15)
  - Haematological disorders (7)
  - Infection (9)
- Mental health (172)
  - Musculoskeletal diseases (10)
  - Neonatal diseases (8)
- Neurological conditions (12)
- Nutritional metabolic and endocrine disorders (55)
  - Oral and dental conditions (2)
- Respiratory diseases (315)
- Skin disorders (64)
  - Symptoms (4)
  - Trauma (6)
- Urological and genital disorders (4)
- Women's health conditions (71)
Sources of uncertainties about the effects of treatments

<table>
<thead>
<tr>
<th>Source</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>From patients</td>
<td>241</td>
</tr>
<tr>
<td>From carers</td>
<td>67</td>
</tr>
<tr>
<td>From clinicians</td>
<td>79</td>
</tr>
<tr>
<td>Research recommendations</td>
<td>408</td>
</tr>
<tr>
<td>Ongoing research</td>
<td>88</td>
</tr>
<tr>
<td>What is the best way of dealing with allergies to cats &amp; dogs to prevent asthma?</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>DUETs module</strong></td>
<td><strong>Asthma</strong></td>
</tr>
<tr>
<td><strong>Record type</strong></td>
<td>Uncertainties identified from patients’ questions</td>
</tr>
<tr>
<td><strong>Source</strong></td>
<td><strong>Asthma UK Adviseline</strong></td>
</tr>
<tr>
<td><strong>Why is there uncertainty?</strong></td>
<td>Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects</td>
</tr>
<tr>
<td><strong>What is needed?</strong></td>
<td>Further research</td>
</tr>
<tr>
<td><strong>Systematic reviews in preparation</strong></td>
<td><em>None identified</em></td>
</tr>
<tr>
<td><strong>Ongoing controlled trials</strong></td>
<td>Manchester Asthma and Allergy Study - Primary prevention of asthma and allergy by allergen avoidance in high risk infants <a href="http://ISRCTN63558189">ISRCTN63558189</a>.</td>
</tr>
<tr>
<td></td>
<td>Prevention of asthma in children at high risk of developing asthma [ISRCTN ISRCTN66748327](<a href="http://ISRCTN">http://ISRCTN</a> ISRCTN66748327).</td>
</tr>
<tr>
<td></td>
<td>Air cleaners for children and adolescents with asthma and dog allergy <a href="http://NCT00220753">NCT00220753</a>.</td>
</tr>
</tbody>
</table>
4. Do research to address uncertainties
Maintaining and improving your performance

14 You must work with colleagues and patients to maintain and improve the quality of your work and promote patient safety. In particular, you must:

(f) help to resolve uncertainties about the effects of treatments
For over 30 years there was uncertainty about whether to use caffeine in newborn infants to reduce apnoeic episodes.

Failure to address this uncertainty has had terrible, enduring consequences for children and adults.
Conclusions Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight.
An exemplar of what is needed

Assessing the effects of administration of systemic corticosteroids in acute traumatic brain injury
A systematic review of existing knowledge

Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials
Philip Alderson, Ian Roberts

Alderson P, Roberts I (1997). *BMJ* 314:1855-9; and *Cochrane Database of Systematic Reviews*.

The review revealed important uncertainty about whether systemic steroids did more good than harm.
<table>
<thead>
<tr>
<th>Steroid</th>
<th>Control (Steroid)</th>
<th>Weight (%)</th>
<th>Odds ratio (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ransohoff 1972</td>
<td>9/17</td>
<td>3.1</td>
<td>0.43 (0.11 to 1.76)</td>
</tr>
<tr>
<td>Alexander 1972</td>
<td>16/55</td>
<td>8.0</td>
<td>0.62 (0.28 to 1.36)</td>
</tr>
<tr>
<td>Faupe1 1976</td>
<td>16/67</td>
<td>8.9</td>
<td>0.24 (0.09 to 0.60)</td>
</tr>
<tr>
<td>Cooper 1979</td>
<td>26/49</td>
<td>4.1</td>
<td>1.22 (0.48 to 3.12)</td>
</tr>
<tr>
<td>Hernesniemi 1979</td>
<td>35/81</td>
<td>10.4</td>
<td>0.99 (0.54 to 1.84)</td>
</tr>
<tr>
<td>Pitts 1980</td>
<td>114/201</td>
<td>12.4</td>
<td>1.24 (0.73 to 2.12)</td>
</tr>
<tr>
<td>Saul 1981</td>
<td>8/50</td>
<td>3.9</td>
<td>0.87 (0.31 to 2.47)</td>
</tr>
<tr>
<td>Braakman 1983</td>
<td>44/81</td>
<td>11.1</td>
<td>0.83 (0.45 to 1.56)</td>
</tr>
<tr>
<td>Giannotta 1984</td>
<td>34/72</td>
<td>3.1</td>
<td>1.15 (0.39 to 3.42)</td>
</tr>
<tr>
<td>Dearden 1986</td>
<td>33/68</td>
<td>5.8</td>
<td>1.84 (0.91 to 3.74)</td>
</tr>
<tr>
<td>Zagara 1987</td>
<td>4/12</td>
<td>1.4</td>
<td>1.00 (0.18 to 5.46)</td>
</tr>
<tr>
<td>Gaab 1994</td>
<td>19/133</td>
<td>9.2</td>
<td>0.91 (0.47 to 1.79)</td>
</tr>
<tr>
<td>Grumme 1995</td>
<td>38/175</td>
<td>18.7</td>
<td>0.83 (0.51 to 1.34)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>396/1061</td>
<td><strong>100</strong></td>
<td><strong>0.91 (0.74 to 1.12)</strong></td>
</tr>
</tbody>
</table>

\((\chi^2 = 15.99; \text{df}=12; Z=0.89)\)

**Fig 1** Summary odds ratio for death at end of study
Addressing an important uncertainty

Because the systematic review and a survey of clinical practice had revealed important uncertainty, a large, publicly-funded, multicentre randomized trial was organised to address the uncertainty.

The trial was registered prospectively on the ISRCTN register,

The protocol for the trial was published in BioMed Central.
Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial

CRASH trial collaborators*

Lancet 2004;364:1321-28
Figure 5: Updated meta-analysis of effect of corticosteroids on death after head injury
The report of the CRASH trial is exemplary because:

- it refers to current uncertainty about the effects of a treatment, manifested in a **systematic review of all the existing evidence**, and in **variations in clinical practice**
- It notes that the **trial was registered and the protocol published** prospectively
- it sets the new results in the context of **an updated systematic review of all of the existing evidence**
- it provides readers with **all the evidence needed for action** to prevent thousands of iatrogenic deaths
How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing

Iain Chalmers, Douglas G Altman

Lancet 1999; 353: 490–93

See Commentary page 428

Review and electronic publication of research protocols

Electronic publication and archiving of medical research
Editorial

Patient Safety Requires a New Way to Publish Clinical Trials

Richard Smith *, Ian Roberts
Box 2. Our Proposed New System

- A systematic review is posted on the Web
- If a new trial is needed, it is registered and a full protocol is devised in light of the systematic review and posted on the Web
- Anybody can comment online on the interpretation of the systematic review data, the importance of the trial question, or the reliability of its methods
- The statistical analysis would be pre-specified and pre-programmed
- When data collection is completed, the entire dataset would be uploaded and the analyses run
- There would be no investigator commentary on the trial data
- The systematic review would be updated to include the new trial
- Journals would not publish trials but rather commentaries and reports on systematic reviews
Reprise

Clinicians and patients need readier access to:

• reports of up-to-date, valid, systematic reviews

• details sufficient to inform their decision making; and

• information about relevant unpublished and ongoing trials
Britain’s gift: a “Medline” of synthesised evidence
Worldwide free access to evidence based resources could transform health care

Richard Smith  editor, BMJ
Iain Chalmers  director

UK Cochrane Centre, Oxford OX2 7LG
For example, we still do not know which treatments are useful for acute stroke, but if every patient in the world experiencing a stroke were admitted to trials we would have enough patients within 24 hours to answer many of these questions. If there were no trials underway addressing the patient’s question then the patient and doctor would send a signal to a central database that the question needed answering. This would allow trials to be designed to answer the questions that mattered most to patients.
Protocols for systematic reviews and consequent research, eg in Cochrane Library and through UK Clinical Trials Gateway

Published systematic reviews and reports of other types of research, eg Cochrane reviews, DARE, articles in Lancet, BMJ, JAMA

Summaries of evidence, including evidence of uncertainty, eg BMJ Clinical Evidence, CKS, BNF, DUETs, Q&A’s

Reports of patient experiences eg DIPEX

Guidelines informed by systematic reviews eg NICE, SIGN

Tools for diagnosis, treatment & monitoring

Prompts & reminders eg Map of Medicine

BETTER INFORMED CHOICES AND DECISIONS
Improve the evidence base

“a national clinical evidence base will be created, housing what local, national and international clinicians believe to be the best available evidence about clinical practice, pathways and models of care and innovations.”

“This will be available to commissioners, practitioners, patients and the public alike.”

“We will work with the relevant bodies, such as NICE, the National Library for Health, the new Health Innovation Council and the Independent Reconfiguration Panel to take this forward.”
There is **shared responsibility** to meet the research information needs of patients and clinicians more effectively.

What can you do?
Address current system failures, in collaboration with others

Promulgate recognition of responsibilities to patients and clinicians among those who can improve access to relevant information

Promote effective coordination, to reduce inefficient use of existing resources

Lobby for relevant and transparent research and reporting practices

Exploit the possibilities offered by electronic publishing
The James Lind Library
Documenting the evolution of fair tests of medical treatments

The James Lind Library has been launched to mark the 250th anniversary of the publication of James Lind’s Treatise of the Scurvy. Lind’s 1753 book contains a systematic review of what had been written about scurvy, which was killing thousands of people every year, as well as one of the earliest accounts of a fair comparison of different medical treatments.

www.jameslindlibrary.org

Email: ichalmers@jameslindlibrary.org